Brown Advisory Inc. boosted its position in Halozyme Therapeutics Inc. (NASDAQ:HALO) by 342.7% during the second quarter, Holdings Channel reports. The fund owned 266,860 shares of the biopharmaceutical company’s stock after buying an additional 206,585 shares during the period. Brown Advisory Inc. owned approximately 0.21% of Halozyme Therapeutics worth $2,303,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. IFP Advisors Inc boosted its stake in Halozyme Therapeutics by 300.8% in the first quarter. IFP Advisors Inc now owns 11,366 shares of the biopharmaceutical company’s stock worth $108,000 after buying an additional 8,530 shares during the last quarter. Commonwealth Equity Services Inc acquired a new stake in Halozyme Therapeutics during the second quarter worth about $109,000. Teacher Retirement System of Texas boosted its stake in Halozyme Therapeutics by 13.7% in the second quarter. Teacher Retirement System of Texas now owns 15,269 shares of the biopharmaceutical company’s stock worth $132,000 after buying an additional 1,842 shares during the last quarter. Meeder Asset Management Inc. acquired a new stake in Halozyme Therapeutics during the second quarter worth about $155,000. Finally, Legal & General Group Plc boosted its stake in Halozyme Therapeutics by 24.6% in the first quarter. Legal & General Group Plc now owns 27,332 shares of the biopharmaceutical company’s stock worth $261,000 after buying an additional 5,392 shares during the last quarter. Institutional investors and hedge funds own 80.41% of the company’s stock.
Halozyme Therapeutics Inc. (NASDAQ:HALO) traded down 1.05% during mid-day trading on Friday, reaching $12.27. The company had a trading volume of 332,622 shares. The stock’s market capitalization is $1.57 billion. Halozyme Therapeutics Inc. has a one year low of $6.96 and a one year high of $18.65. The company’s 50-day moving average is $10.49 and its 200-day moving average is $9.80.
Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.21) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.06. The firm earned $33.30 million during the quarter, compared to analyst estimates of $29.94 million. Halozyme Therapeutics had a negative return on equity of 234.15% and a negative net margin of 44.90%. The company’s revenue for the quarter was down 23.3% on a year-over-year basis. During the same period in the previous year, the company posted $0.02 EPS. Equities research analysts anticipate that Halozyme Therapeutics Inc. will post ($0.91) earnings per share for the current year.
A number of analysts have recently issued reports on HALO shares. Canaccord Genuity reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Halozyme Therapeutics in a research report on Monday, June 6th. Wells Fargo & Co. reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research report on Wednesday, June 8th. Finally, Piper Jaffray Cos. raised their price objective on Halozyme Therapeutics from $15.00 to $18.00 and gave the company an “overweight” rating in a research report on Friday, September 16th. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $16.11.
Halozyme Therapeutics Company Profile
Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of enzymes segment. This segment also includes research and development, and bulk rHuPH20 manufacturing activities conducted under its collaborative agreements with third parties, and product sales of Hylenex recombinant.
Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics Inc. (NASDAQ:HALO).
Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.